Cure51 appoints Ashley Lakner as chief scientific officer

Related Company

Cure51

Related Strategy

Digital Medicine

Related Deal lead

Simon Turner

We’re thrilled to welcome Ashley Lakner, PhD, our new Chief Scientific Officer (CSO)!

Ashley joins our team with an exceptional track record in oncology drug discovery and precision medicine. Most recently leading Oncology Discovery at Roche pRED, and previously as VP of Precision Molecular Oncology at Bayer, Ashley advanced multiple molecules across key modalities into early clinical development through rigorous translational research.

Ashley brings deep scientific expertise, extensive drug discovery experience and proven leadership of multidisciplinary teams, helping us advance our mission of turning breakthrough biology into meaningful patient impact.

Welcome to the team!

Cure51 appoints Ashley Lakner as chief scientific officer

T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease

AFYREN and MINASOLVE Announce Partnership Agreement to Jointly Develop Key Bio-Based Molecules for the Fragrances Industry at Industrial Scale

Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing to Advance a New Generation of Therapies for Myeloproliferative Neoplasms

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition

Biotalys’ First Commercial Biofungicide EVOCA® NG Approved for Large-Scale Commercial Field Trials in the Netherlands

BrightHeart Expands Its AI Platform in Europe to Bring Greater Confidence and Consistency to Prenatal Ultrasound